Bill & Melinda Gates Foundation - Global Grand Challenges: Innovations for Gram-Negative Antibiotic Discovery
Event details
| Date | 25.03.2025 |
| Category | Conferences - Seminars |
Aim: The ultimate objective of Gr-ADI will be to enable discovery of safe and simple first-line broad-spectrum drugs for syndromic management, through:
Proposals must address at least one of the following themes:
This Grand Challenge is a collaboration between the Gates Foundations, Nova Nordisk Foundation and Wellcome, but each funder will make independent funding decisions. Applicants successful at the preliminary stage will be invited to submit a full application via GF, NNF, or Wellcome as applicable. Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge, including the terms and conditions of Wellcome, the Gates Foundation, and the Novo Nordisk Foundation, Rules and Guidelines, Application Instructions, and Frequently Asked Questions.
Funding: max. $5,000,000 (incl. 15% overheads)
Duration: max. 3 years
Eligibility: This initiative is open to nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. Applications from institutions based in LMICs and projects led by women and other groups that are historically under-represented in the drug discovery field are encouraged. All applications received will then be reviewed on their merits.
How to Apply: Applicants should apply through the application portal. The letter of inquiry, with a scientific proposal should not to exceed five pages. The budget table and narrative can be found here. Budgets should include 15% indirect costs (max. allowed amongst potential funders). Upon registration, applicants must provide information about the tax status of their organization; please contact the Research Office for assistance.
Deadline: 25 March 2025 – 11:30 am PT
Further information
- Development of novel and emerging biological, chemical, and AI tools that could be applied broadly for antibiotic discovery to identify new antibiotic targets.
- Application of these innovative approaches to generate chemical starting points for project-based drug discovery.
- Fostering a collective mindset to address gaps in knowledge, solve problems, and manage a portfolio of targets and hits
Proposals must address at least one of the following themes:
- Development of genome-scale tools or other innovative technologies to identify new chemical starting points linked to targets as well as assessment of potential drug target vulnerability, singly or in combination.
- Development of innovative technologies to select targets and chemical leads with a very high bar to resistance.
- Gaining a better understanding of the chemistry underlying penetration of compounds to different compartments of the bacterial cell to build a platform to rapidly test whether compounds reach and accumulate at their target.
- Development of novel and coordinated approaches to identifying new chemical leads for clinically or in vivo validated drug targets, for which there is currently no agent in Phase 3.
This Grand Challenge is a collaboration between the Gates Foundations, Nova Nordisk Foundation and Wellcome, but each funder will make independent funding decisions. Applicants successful at the preliminary stage will be invited to submit a full application via GF, NNF, or Wellcome as applicable. Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge, including the terms and conditions of Wellcome, the Gates Foundation, and the Novo Nordisk Foundation, Rules and Guidelines, Application Instructions, and Frequently Asked Questions.
Funding: max. $5,000,000 (incl. 15% overheads)
Duration: max. 3 years
Eligibility: This initiative is open to nonprofit organizations, for-profit companies, international organizations, government agencies, and academic institutions. Applications from institutions based in LMICs and projects led by women and other groups that are historically under-represented in the drug discovery field are encouraged. All applications received will then be reviewed on their merits.
How to Apply: Applicants should apply through the application portal. The letter of inquiry, with a scientific proposal should not to exceed five pages. The budget table and narrative can be found here. Budgets should include 15% indirect costs (max. allowed amongst potential funders). Upon registration, applicants must provide information about the tax status of their organization; please contact the Research Office for assistance.
Deadline: 25 March 2025 – 11:30 am PT
Further information
- More information about the program is available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free